Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,108
archived clinical trials in
Lupus

A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cumberland, MD
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cumberland, MD
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Clair Shores, MI
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Clair Shores, MI
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Duluth, MN
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Duluth, MN
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Hattiesburg, MS
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Hattiesburg, MS
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Las Vegas, NV
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Freehold, NJ
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Freehold, NJ
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Voorhees, NJ
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Voorhees, NJ
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Las Cruces, NM
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Las Cruces, NM
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Albany, NY
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Manhasset, NY
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Manhasset, NY
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New York, NY
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Plainview, NY
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Plainview, NY
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Roslyn, NY
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Roslyn, NY
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chapel Hill, NC
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Raleigh, NC
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Rocky Mount, NC
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Rocky Mount, NC
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cincinnati, OH
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cleveland, OH
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Toledo, OH
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Toledo, OH
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Duncansville, PA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Duncansville, PA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Wyomissing, PA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Wyomissing, PA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Charleston, SC
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cookeville, TN
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cookeville, TN
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Knoxville, TN
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Amarillo, TX
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Amarillo, TX
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Austin, TX
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Nassau Bay, TX
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Nassau Bay, TX
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Round Rock, TX
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Round Rock, TX
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Victoria, TX
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Victoria, TX
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint George, UT
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint George, UT
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Spokane, WA
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Clarksburg, WV
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Clarksburg, WV
Click here to add this to my saved trials
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
St Leonards,
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
St Leonards,
Click here to add this to my saved trials
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Hemet, CA
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Hemet, CA
Click here to add this to my saved trials
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Huntington Beach, CA
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
La Jolla, CA
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Leandro, CA
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Leandro, CA
Click here to add this to my saved trials
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Torrance, CA
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Torrance, CA
Click here to add this to my saved trials
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Westlake Village, CA
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Westlake Village, CA
Click here to add this to my saved trials
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Denver, CO
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bridgeport, CT
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bridgeport, CT
Click here to add this to my saved trials